UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) November 4, 2013
OphthaliX Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 000-52545 | 88-0445169 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
10 Bareket Street, Petach Tikva, Israel | 4951778 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: +(972) 3-9241114
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
. Written communications pursuant to Rule 425 under the Securities Act
. Soliciting material pursuant to Rule 14a-12 under the Exchange Act
. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 8.01
Other Events.
On November 4, 2013, the Company provided an update that it anticipates that during the first quarter of 2014 it will initiate enrolment for its Phase II trial of CF101 for the treatment of uveitis.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OphthaliX Inc.
Date: November 4, 2013
By: /s/ Barak Singer
Barak Singer, Chief Executive Officer
2